Analyst Scoreboard: 5 Ratings For Twist Bioscience
Portfolio Pulse from Benzinga Insights
Twist Bioscience (NASDAQ:TWST) has received mixed ratings from analysts, with a recent shift towards a more positive outlook. Over the past three months, 5 analysts have provided ratings, with the latest average 12-month price target for TWST being $43.6, marking a significant increase from the previous target of $31. This positive adjustment reflects analysts' growing optimism about the company's performance and market position. Twist Bioscience, a synthetic biology company, has shown a revenue growth rate of 31.81% as of December 31, 2023, despite trailing behind its industry peers. The company's financial health is highlighted by its efficient cost management, impressive ROE and ROA, and a prudent approach to debt management.
April 10, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience has seen a positive shift in analyst sentiment, with an updated average 12-month price target of $43.6, reflecting a 40.65% increase from the previous target. The company's recent revenue growth and strong financial indicators, such as ROE and ROA, contribute to this optimistic outlook.
The increase in the average price target for TWST by analysts indicates a strong belief in the company's future growth and market position. This optimism is supported by the company's recent revenue growth, efficient cost management, and strong financial performance metrics such as ROE and ROA. The positive analyst ratings and adjustments in price targets suggest a bullish outlook for TWST in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100